Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation

被引：3
|
作者：
Wood, Brian R. [1 ]
Kassaye, Seble G. [2 ]
Gerstoft, Jan [3 ]
机构：
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA USA
[2] Georgetown Univ, Dept Med, Washington, DC USA
[3] Univ Copenhagen, Dept Infect Dis, Rigshosp, Copenhagen, Denmark
来源：
AIDS | 2023年 / 37卷 / 04期
关键词：
RILPIVIRINE; FAILURE;
D O I：
10.1097/QAD.0000000000003476
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：689 / 691
页数：3
相关论文
共 50 条
  • [21] Rilpivirine long-acting for the prevention and treatment of HIV infection
    Ferretti, Francesca
    Boffito, Marta
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 300 - 307
  • [22] Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV
    Thoueille, Paul
    Saldanha, Susana Alves
    Schaller, Fabian
    Choong, Eva
    Veuve, Francois
    Munting, Aline
    Cavassini, Matthias
    Braun, Dominique
    Gunthard, Huldrych F.
    Ramirez, Jessy J. Duran
    Surial, Bernard
    Furrer, Hansjakob
    Rauch, Andri
    Ustero, Pilar
    Calmy, Alexandra
    Stockle, Marcel
    Di Benedetto, Caroline
    Bernasconi, Enos
    Schmid, Patrick
    Marzolini, Catia
    Girardin, Francois R.
    Buclin, Thierry
    Decosterd, Laurent A.
    Guidi, Monia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine
    Alagaratnam, Jasmini
    Kelly, Niall
    Dustan, Simon
    Naous, Nadia
    Nwanbila, Modest
    Byrne, Ruth
    Girometti, Nicolo
    Asboe, David
    Taylor, Graham P.
    Boffito, Marta
    AIDS, 2025, 39 (01) : 95 - 98
  • [24] Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection
    Zeuli, John D.
    Rivera, Christina G.
    Smith, Bradley L.
    Otto, Ashley
    Temesgen, Zelalem
    DRUGS OF TODAY, 2022, 58 (12) : 555 - 576
  • [25] Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area
    Nguyen, Ngan M.
    Kavanagh, Rebecca
    Gozar, Martin
    Cabral, Danielle
    Goetz, Holly
    Cha, Agnes
    Mcgowan, Joseph P.
    Pao, Megan L.
    AIDS PATIENT CARE AND STDS, 2024, 38 (03) : 115 - 122
  • [26] Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic
    Liegeon, Geoffroy
    Kaperak, Christopher
    Friedman, Eleanor E.
    Djuricich, Paul
    Dawdani, Alicia
    Stafford, Kane
    Plotkin, Sophie
    Schmitt, Jessica
    Hazra, Aniruddha
    Christopoulos, Katerina A.
    Schneider, John A.
    Mcnulty, Moira C.
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [27] Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine
    Maguire, Christina
    Rueve, Kaitlyn
    Farmer, Eric
    Huesgen, Emily
    Karaj, Antoneta
    Binkley, Amanda
    Mounzer, Karam
    Brizzi, Marisa
    Chary, Pallavi
    Sung, Peter
    Graziani, Amy
    Hiserodt, Emily
    Baron, Jillian
    Koenig, Helen
    Short, William R.
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [28] Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
    Castelli, Alessandro
    Lanzafame, Massimiliano
    Morra, Matteo
    Bertoldi, Marco
    Delama, Andrea
    Fait, Daniela
    Vento, Sandro
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (05) : 283 - 285
  • [29] Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials
    Patel, Parul
    Ford, Susan L.
    Baker, Mark
    Meyer, Claudia
    Garside, Louise
    D'Amico, Ronald
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Polli, Joseph W.
    Seal, Ciara
    Yaguee Munoz, Itziar
    Thiagarajah, Shanker
    Birmingham, Eileen
    Spreen, William R.
    Baugh, Bryan
    van Wyk, Jean
    Vannappagari, Vani
    HIV MEDICINE, 2023, 24 (05) : 568 - 579
  • [30] Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China
    Li, Mengqing
    Guan, Hongjing
    Zhong, Mingli
    Di, Xiaoyun
    Yu, Nawei
    Chen, Chen
    Cai, Rentian
    Wei, Hongxia
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2025, 41 (02) : 107 - 112
12345